BHCM
PRAX icon

Brevan Howard Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Brevan Howard Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$495K Buy
1,478
+506
+52% +$160K ﹤0.01% 1454
2026
Q1 		$313K Buy
+972
New +$301K ﹤0.01% 1588
2025
Q3 		– Sell
-8,503
Closed -$358K – 2210
2025
Q2 		$358K Buy
+8,503
New +$324K ﹤0.01% 1488
2024
Q2 		– Sell
-16,180
Closed -$987K – 1334
2024
Q1 		$987K Buy
+16,180
New +$726K 0.01% 272

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Brevan Howard Capital Management's PRAX Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Praxis Precision Medicines (PRAX) stake by 52% in Q2 2026, buying an estimated $160K and bringing the position to 1,478 shares worth $495K. The position accounts for ﹤0.01% of the portfolio, ranked #1454.

Brevan Howard Capital Management first reported a position in PRAX in Q1 2024 and has held it in 4 quarters since. The position peaked at $987K in Q1 2024. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Brevan Howard Capital Management held 1,478 shares of Praxis Precision Medicines worth $495K as of Q2 2026.
  • Brevan Howard Capital Management bought 506 Praxis Precision Medicines shares in Q2 2026, an estimated $160K.
  • Praxis Precision Medicines made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1454 holding.
  • Brevan Howard Capital Management first reported a position in Praxis Precision Medicines in Q1 2024 and has held it in 4 quarters since.
  • Brevan Howard Capital Management's Praxis Precision Medicines position peaked at $987K in Q1 2024.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.